{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:43Z","timestamp":1781647183573,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is a rare, progressive neuromuscular disease. Long-term care is primarily provided by unpaid family-caregivers. This time trade-off (TTO) study aimed to generate family-caregiver utility values associated with different stages of DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight vignettes were developed to reflect the experience of caring for patients with DMD across health states (HS) defined in the Project HERCULES model. Vignettes were informed by literature and input from family-caregivers and healthcare professionals. TTO interviews were conducted online with members of the UK general public. Participants reviewed all vignettes and completed HS ranking, visual analog scale (VAS) ratings, and TTO valuation tasks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>200 participants (mean age 44.0 years, 51% female) completed interviews. Mean utility scores were highest for HS1 (early ambulatory: 0.717) and lowest for HS8 (no hand-to-mouth function, full-time ventilation: 0.477). VAS scores showed a similar pattern, with HS1 scoring 65.49 and HS8 scoring 31.665.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the increasing burden on family-caregivers as DMD progresses, with declining health-related quality of life across HS. The resulting utility values support inclusion of family-caregiver outcomes in future DMD cost-effectiveness models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01055-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:18:56Z","timestamp":1775791136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating health-state utility values for family-caregivers of patients with Duchenne muscular dystrophy using time trade-off valuation"],"prefix":"10.1186","volume":"10","author":[{"given":"Oktawia","family":"Borecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-4216","authenticated-orcid":false,"given":"Samuel","family":"Llewellyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ione","family":"Woollacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Fellows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M.","family":"Biggane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Reviews Disease Primers 7(1). https:\/\/doi.org\/10.1038\/s41572-021-00248-3","DOI":"10.1038\/s41572-021-00248-3"},{"key":"1055_CR2","doi-asserted-by":"publisher","unstructured":"Uttley L, Carlton J, Woods H, Brazier J (2018) A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes 16(1). https:\/\/doi.org\/10.1186\/s12955-018-1062-0","DOI":"10.1186\/s12955-018-1062-0"},{"key":"1055_CR3","doi-asserted-by":"publisher","unstructured":"Baiardini I, Minetti C, Bonifacino S et al (2011) Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol 26(6):707\u2013713. https:\/\/doi.org\/10.1177\/0883073810389043","DOI":"10.1177\/0883073810389043"},{"key":"1055_CR4","doi-asserted-by":"publisher","unstructured":"Landfeldt E, Edstr\u00f6m J, Buccella F, Kirschner J, Lochm\u00fcller H (2018) Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol 60(10):987\u2013996. https:\/\/doi.org\/10.1111\/dmcn.13934","DOI":"10.1111\/dmcn.13934"},{"key":"1055_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39597","author":"A Balidemaj","year":"2023","unstructured":"Balidemaj A, Parsamanesh P, Vysochyn M (2023) Exploring the dynamics of caring for a child with a terminal illness of Duchenne Muscular Dystrophy (DMD) and Its copious components on the caregivers. Cureus. https:\/\/doi.org\/10.7759\/cureus.39597","journal-title":"Cureus"},{"key":"1055_CR6","doi-asserted-by":"publisher","unstructured":"Landfeldt E, Lindgren P, Bell C et al (2016) Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol 58(5). https:\/\/doi.org\/10.1111\/dmcn.12938","DOI":"10.1111\/dmcn.12938"},{"key":"1055_CR7","doi-asserted-by":"publisher","unstructured":"de Moura M, Wutzki H, Voos M, Resende M, Reed U, Hasue R (2015) Is functional dependence of Duchenne muscular dystrophy patients determinant of the quality of life and burden of their caregivers? Arq Neuropsiquiatr 73(1). https:\/\/doi.org\/10.1590\/0004-282X20140194","DOI":"10.1590\/0004-282X20140194"},{"key":"1055_CR8","doi-asserted-by":"publisher","unstructured":"Patterson G, Conner H, Groneman M, Blavo C, Parmar M (2023) Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol 947. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175675","DOI":"10.1016\/j.ejphar.2023.175675"},{"key":"1055_CR9","doi-asserted-by":"publisher","unstructured":"D\u2019Ambrosio E, Mendell J (2023) Evolving therapeutic options for the treatment of Duchenne muscular dystrophy. Neurotherapeutics 20(6). https:\/\/doi.org\/10.1007\/s13311-023-01423-y","DOI":"10.1007\/s13311-023-01423-y"},{"key":"1055_CR10","doi-asserted-by":"publisher","unstructured":"Heydemann A, Siemionow M (2023) A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines 11(3). https:\/\/doi.org\/10.3390\/biomedicines11030830","DOI":"10.3390\/biomedicines11030830"},{"key":"1055_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cns3.20076","author":"A Veerapandiyan","year":"2024","unstructured":"Veerapandiyan A, Connolly A, Mathews K et al (2024) Access to novel therapies for Duchenne muscular dystrophy\u2014Insights from expert treating physicians. Ann Child Neurol Soc 2:184\u2013188. https:\/\/doi.org\/10.1002\/cns3.20076","journal-title":"Annals Child Neurol Soc"},{"key":"1055_CR12","doi-asserted-by":"publisher","unstructured":"Henry E, Al-Janabi H, Brouwer W et al (2024) Recommendations for emerging good practice and future research in relation to family and caregiver health spillovers in health economic evaluations:a report of the SHEER task force. PharmacoEconomics 2024 42(3):343\u2013362. https:\/\/doi.org\/10.1007\/s40273-023-01321-3","DOI":"10.1007\/s40273-023-01321-3"},{"key":"1055_CR13","doi-asserted-by":"publisher","unstructured":"Berkelbach van der Spenkel EE, Nijhof SL, Dalmeijer GW et al (2022) Psychosocial functioning in adolescents growing up with chronic disease: The Dutch HBSC study. Eur J Pediatr 181(2). https:\/\/doi.org\/10.1007\/s00431-021-04268-9","DOI":"10.1007\/s00431-021-04268-9"},{"key":"1055_CR14","doi-asserted-by":"publisher","unstructured":"Brouwer W (2019) The inclusion of spillover effects in economic evaluations: not an optional extra. PharmacoEconomics 37(4):451\u2013456. https:\/\/doi.org\/10.1007\/s40273-018-0730-6","DOI":"10.1007\/s40273-018-0730-6"},{"key":"1055_CR15","doi-asserted-by":"publisher","unstructured":"Pennington B (2020) Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals. Value Health 23(10):1349\u20131357. https:\/\/doi.org\/10.1016\/j.jval.2020.05.017","DOI":"10.1016\/j.jval.2020.05.017"},{"key":"1055_CR16","doi-asserted-by":"publisher","unstructured":"Pennington B, Eaton J, Hatswell A, Taylor H (2022) Carers\u2019 health-related quality of life in global health technology assessment: guidance, case studies and recommendations. PharmacoEconomics 40(9):837\u2013850. https:\/\/doi.org\/10.1007\/s40273-022-01164-4","DOI":"10.1007\/s40273-022-01164-4"},{"key":"1055_CR17","unstructured":"NICENICE health technology evaluations: the manual. Process and methods [PMG36]. Accessed 5 January 2024. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation#measuring-and-valuing-health-effects-in-cost-utility-analyses"},{"key":"1055_CR18","doi-asserted-by":"publisher","unstructured":"Looby A, Dymond A, Green W, Wentzel H, Malottki K (2024) Uncertainties in evaluating the health-related quality of life and disease burden of people with rare diseases and their caregivers in NICE HST submissions. Orphanet J Rare Dis 19(1). https:\/\/doi.org\/10.1186\/s13023-024-03382-9","DOI":"10.1186\/s13023-024-03382-9"},{"issue":"6","key":"1055_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s11136-025-03937-8","volume":"34","author":"PA Powell","year":"2025","unstructured":"Powell PA, Carlton J, Peasgood T, Chandler F, Godfrey J, Reuben E (2025) Understanding the health-related quality of life impacts of caring for children and adolescents with rare progressive life-limiting conditions: key challenges and future research priorities. Qual Life Res 34(6):1579\u20131585. https:\/\/doi.org\/10.1007\/s11136-025-03937-8","journal-title":"Qual Life Res"},{"key":"1055_CR20","doi-asserted-by":"publisher","unstructured":"Williams K, Davidson I, Rance M, Buesch K, Acaster S (2021) A qualitative study on the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy. J Patient Rep Outcomes 5(1). https:\/\/doi.org\/10.1186\/s41687-021-00344-8","DOI":"10.1186\/s41687-021-00344-8"},{"key":"1055_CR21","doi-asserted-by":"publisher","unstructured":"Powell P, Carlton J, Rowen D et al (2022) Measuring what matters: little evidence supporting the content validity of EQ-5D in people with Duchenne muscular dystrophy and their caregivers. Med Decis Making 42(2):139\u2013140. https:\/\/doi.org\/10.1177\/0272989X211062237","DOI":"10.1177\/0272989X211062237"},{"key":"1055_CR22","unstructured":"NICE. National Institute for Health and Care Excellence: CHTE methods review. Health-related quality of life. Task and finish group report. Accessed 5 January 2024. https:\/\/rees-france.com\/wp-content\/uploads\/2020\/12\/2020-CHTE-2020-Health-related-quality-of-life-.pdf"},{"key":"1055_CR23","doi-asserted-by":"publisher","unstructured":"Landfeldt E, Lindgren P, Bell C et al (2016) Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol 263(5);906\u2013915. https:\/\/doi.org\/10.1007\/s00415-016-8080-9","DOI":"10.1007\/s00415-016-8080-9"},{"key":"1055_CR24","doi-asserted-by":"publisher","unstructured":"Gallop K, Foerster D, Lawrence C, Denjean E, Van Der Wild J, Acaster S (2020) PMS61 estimation of health utilities for non-ambulatory Duchenne muscular dystrophy (DMD) patients and their caregivers. Value Health 23(2). https:\/\/doi.org\/10.1016\/j.jval.2020.08.1192","DOI":"10.1016\/j.jval.2020.08.1192"},{"key":"1055_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00450-x","author":"J Broomfield","year":"2024","unstructured":"Broomfield J, Hill M, Chandler F et al (2024) Developing a natural history model for Duchenne muscular dystrophy. Pharmacoecon Open 8(1):79\u201389. https:\/\/doi.org\/10.1007\/s41669-023-00450-x","journal-title":"PharmacoEconomics - Open"},{"key":"1055_CR26","unstructured":"Broomfield J, Hill M, Crowther MJ et al (2020) Project HERCULES: the challenges of estimating multi-state model transitions in rare diseases: creating a natural history model for Duchenne muscular dystrophy (DMD). presented at: European Conference on Rare Diseases (ECRD); virtual"},{"key":"1055_CR27","doi-asserted-by":"publisher","unstructured":"Carlton J, Powell PA, Project HERCULES CarerGroup (2022) Measuring carer quality of life in Duchenne muscular dystrophy: a systematic review of the reliability and validity of self-report instruments using COSMIN. Health Qual Life Outcomes 20(1):57 https:\/\/doi.org\/10.1186\/s12955-022-01964-4","DOI":"10.1186\/s12955-022-01964-4"},{"key":"1055_CR28","doi-asserted-by":"publisher","unstructured":"Hall F, de Freitas H, Kerr C et al (2019) Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res 28(5):1191\u20131199. https:\/\/doi.org\/10.1007\/s11136-019-02117-9","DOI":"10.1007\/s11136-019-02117-9"},{"key":"1055_CR29","doi-asserted-by":"publisher","unstructured":"Martin A, Ferri Grazzi E, Mighiu C et al (2023) Health state utilities for beta-thalassemia: a time trade-off study. Eur J Health Econ 24(1):27\u201338. https:\/\/doi.org\/10.1007\/s10198-022-01449-7","DOI":"10.1007\/s10198-022-01449-7"},{"key":"1055_CR30","unstructured":"ONS. Office for National Statistics: Marriage and civil partnership status in England and Wales: Census 2021. Accessed 11 January 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/marriagecohabitationandcivilpartnerships\/articles\/marriageandcivilpartnershipstatusenglandandwalescensus2021\/2023-02-22"},{"key":"1055_CR31","unstructured":"ONS. Office for National Statistics: Education, England and Wales: Census 2021. Accessed 11 January 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/educationandchildcare\/bulletins\/educationenglandandwales\/census2021#highest-level-of-qualification"},{"key":"1055_CR32","unstructured":"ONS. Office for National Statistics: Economic activity status, England and Wales: Census 2021. Accessed 11 January 2024. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/employmentandemployeetypes\/bulletins\/economicactivitystatusenglandandwales\/census2021"},{"key":"1055_CR33","unstructured":"ONS. Office for National Statistics: Population estimates for the UK, England, Wales, Scotland and Northern Ireland: mid-2021. Accessed 26 January 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2021"},{"key":"1055_CR34","unstructured":"ONS. Office for National Statistics: Ethnic group, England and Wales: Census 2021. Accessed 11 January 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/culturalidentity\/ethnicity\/bulletins\/ethnicgroupenglandandwales\/census2021"},{"key":"1055_CR35","unstructured":"ONS. Office for National Statistics (2021) Overview of the UK population: January 2021. Accessed 11 January 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/articles\/overviewoftheukpopulation\/january"},{"key":"1055_CR36","doi-asserted-by":"publisher","unstructured":"Lipman S (2021) Time for tele-TTO? Lessons learned from digital interviewer-assisted time trade-off data collection. Patient 14(5):459\u2013469. https:\/\/doi.org\/10.1007\/s40271-020-00490-z","DOI":"10.1007\/s40271-020-00490-z"},{"key":"1055_CR37","doi-asserted-by":"publisher","unstructured":"Matza L, Stewart K, Lloyd A, Rowen D, Brazier J (2021) Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health 24(6):812\u2013821. https:\/\/doi.org\/10.1016\/j.jval.2020.12.017","DOI":"10.1016\/j.jval.2020.12.017"},{"issue":"4","key":"1055_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hec.2804","volume":"22","author":"AE Attema","year":"2013","unstructured":"Attema AE, Versteegh MM, Oppe M, Brouwer WBF, Stolk EA (2013) Lead time TTO: leading to better health state valuations? Health Econ 22(4):376\u2013392. https:\/\/doi.org\/10.1002\/hec.2804","journal-title":"Health Econ"},{"key":"1055_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/ppa.S160662","volume":"12","author":"EW Davies","year":"2018","unstructured":"Davies EW, Llewellyn S, Beaudet A, Kosmas CE, Gin-Sing W, Doll HA (2018) Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence 12:1079\u20131088. https:\/\/doi.org\/10.2147\/ppa.S160662","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"1055_CR40","doi-asserted-by":"publisher","first-page":"A513","DOI":"10.1016\/j.jval.2016.09.968","volume":"19","author":"RS Ballinger","year":"2016","unstructured":"Ballinger RS, Macey J, Lloyd AJ, Brazier JE (2016) Utilities associated with the number of days on parenteral support in the treatment of short bowel syndrome. Value Health 19(7):A513. https:\/\/doi.org\/10.1016\/j.jval.2016.09.968","journal-title":"Value Health"},{"issue":"4","key":"1055_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F (2014) A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health 17(4):445\u2013453. https:\/\/doi.org\/10.1016\/j.jval.2014.04.002","journal-title":"Value Health"},{"key":"1055_CR42","doi-asserted-by":"publisher","unstructured":"Devlin N, Shah K, Feng Y, Mulhern B, van Hout B (2018) 2018;27(1)doi Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ 27:7\u201322. https:\/\/doi.org\/10.1002\/hec.3564","DOI":"10.1002\/hec.3564"},{"key":"1055_CR43","doi-asserted-by":"publisher","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095\u20131108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002","DOI":"10.1097\/00005650-199711000-00002"},{"key":"1055_CR44","doi-asserted-by":"publisher","unstructured":"van Hout B, Janssen M, Feng Y et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5):708\u2013715. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"1055_CR45","doi-asserted-by":"publisher","unstructured":"Scope A, Bhadhuri A, Pennington B (2022) Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life. Value Health 25(9):1644\u20131653. https:\/\/doi.org\/10.1016\/j.jval.2022.02.008","DOI":"10.1016\/j.jval.2022.02.008"},{"key":"1055_CR46","doi-asserted-by":"publisher","unstructured":"Charlton V (2020) NICE and Fair? Health Technology Assessment Policy Under the UK\u2019s National Institute for Health and Care Excellence, 1999\u20132018. Health Care Anal 28(3):193\u2013227. https:\/\/doi.org\/10.1007\/s10728-019-00381-x","DOI":"10.1007\/s10728-019-00381-x"},{"key":"1055_CR47","doi-asserted-by":"publisher","unstructured":"Acaster S, Williams K, Skrobanski H, Buesch K (2022) Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency. Future Neurol 17(2):FNL58. https:\/\/doi.org\/10.2217\/fnl-2022-0004","DOI":"10.2217\/fnl-2022-0004"},{"key":"1055_CR48","doi-asserted-by":"publisher","unstructured":"Reed C, Barrett A, Lebrec J et al (2017) How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer\u2019s disease? Health Qual Life Outcomes 15(16). https:\/\/doi.org\/10.1186\/s12955-017-0591-2","DOI":"10.1186\/s12955-017-0591-2"},{"key":"1055_CR49","doi-asserted-by":"publisher","unstructured":"Schwartz C, Stark R, Audhya I, Gooch K (2021) Characterizing the quality-of-life impact of Duchenne muscular dystrophy on caregivers: a case-control investigation. J Patient Rep Outcomes 5(1):124. https:\/\/doi.org\/10.1186\/s41687-021-00386-y","DOI":"10.1186\/s41687-021-00386-y"},{"issue":"5","key":"1055_CR50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40273-024-01367-x","volume":"42","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Sandhu H (2024) Economic evaluations of treatments for Duchenne muscular dystrophy: the caregiver QALY trap. PharmacoEconomics 42(5):475\u2013478. https:\/\/doi.org\/10.1007\/s40273-024-01367-x","journal-title":"PharmacoEconomics"},{"key":"1055_CR51","unstructured":"McNulty R (2024) Posters characterize DMD caregiver experiences, impact of gene therapy on caregiving demands. Accessed 20 May 2024. https:\/\/www.ajmc.com\/view\/posters-characterize-dmd-caregiver-experiences-impact-of-gene-therapy-on-caregiving-demands"},{"key":"1055_CR52","doi-asserted-by":"publisher","unstructured":"Schwartz C, Stark R, Borowiec K, Audhya I, Gooch K (2022) Interplay of disability, caregiver impact, and out-of-pocket expenditures in Duchenne muscular dystrophy: a cohort study. J Patient Rep Outcomes 6(1). https:\/\/doi.org\/10.1186\/s41687-022-00425-2","DOI":"10.1186\/s41687-022-00425-2"},{"key":"1055_CR53","unstructured":"NICE. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. Highly specialised technologies guidance. Accessed 9 January 2024. https:\/\/www.nice.org.uk\/guidance\/hst22\/resources\/ataluren-for-treating-duchenne-muscular-dystrophy-with-a-nonsense-mutation-in-the-dystrophin-gene-pdf-50216315955397"},{"key":"1055_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28102","author":"S Rosero","year":"2024","unstructured":"Rosero S, Weinstein J, Seabury J et al (2024) Patient- and caregiver-reported impact of symptoms in Duchenne muscular dystrophy. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.28102","journal-title":"Muscle Nerve"},{"key":"1055_CR55","unstructured":"PCORI. Patient-Centered Outcomes Research Institute: Engagement in Research: PCORI\u2019s Foundational Expectations for Partnerships. Accessed 3 June 2024. https:\/\/www.pcori.org\/engagement\/engagement-resources\/engagement-research-pcoris-foundational-expectations-partnerships"},{"key":"1055_CR56","unstructured":"FDA. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. Accessed 3 June 2024. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"1055_CR57","doi-asserted-by":"publisher","unstructured":"Rowen D, Mukuria C, Bray N et al (2022) Assessing the comparative feasibility, acceptability and equivalence of videoconference interviews and face-to-face interviews using the time trade-off technique. Soc Sci Med 309:115227. https:\/\/doi.org\/10.1016\/j.socscimed.2022.115227","DOI":"10.1016\/j.socscimed.2022.115227"},{"key":"1055_CR58","doi-asserted-by":"publisher","unstructured":"Finch A, Meregaglia M, Ciani O, Roudijk B, Jommi C (2022) An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med 292:114519. https:\/\/doi.org\/10.1016\/j.socscimed.2021.114519","DOI":"10.1016\/j.socscimed.2021.114519"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01055-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:43:56Z","timestamp":1781646236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01055-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01055-8","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was granted by a central independent review board (Solutions IRB, Yarnell, AZ, US). All participants provided informed consent electronically prior to undertaking any protocol-related activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participant data has been anonymized, and participants were informed that if information about this study was published, they would not be identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AMB and LR are employees of Pfizer Ltd. IW was an employee of Pfizer Ltd. during the conduct of this study. AF, JL and SL are employees of Vitaccess, which served as a paid consultant to Pfizer Ltd. in connection with the conduct of this study and the development of this manuscript. OB was an employee of Vitaccess during the conduct of this study and development of this manuscript and is now an employee of OPEN Health. CB was an employee of Vitaccess during the conduct of this study and development of this manuscript and is now an employee of Clarivate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}